Beauchamp N J, Taybert J, Champion M P, Layet V, Heinz-Erian P, Dalton A, Tanner M S, Pronicka E, Sharrard M J
Academic Unit of Child Health, University of Sheffield, Stephenson Wing, Sheffield Children's NHS Trust, Western Bank, Sheffield, S10 2TH, UK.
J Inherit Metab Dis. 2007 Oct;30(5):722-34. doi: 10.1007/s10545-007-0499-9. Epub 2007 Aug 21.
Deficiency of liver glycogen phosphorylase in glycogen storage disease (GSD) type VI results in a reduced ability to mobilize glucose from glycogen. Six mutations of the PYGL gene, which encodes the liver isoform of the enzyme, have been identified in the literature. We have characterized eight patients from seven families with GSD type VI and identified 11 novel PYGL gene defects. The majority of the mutations were missense, resulting in the substitution of highly conserved residues. These could be grouped into those that were predicted to affect substrate binding (p.V456M, p.E673K, p.S675L, p.S675T), pyridoxal phosphate binding (p.R491C, p.K681T), or activation of glycogen phosphorylase (p.Q13P) or that had an unknown effect (p.N632I and p.D634H). Two mutations were predicted to result in null alleles, p.R399X and [c.1964_1969inv6;c.1969+1_+4delGTAC]. Only 7 of the 23 (30%) reported PYGL alleles carry nonsense, splice site or frameshift mutations compared to 68-80% of affected alleles of the highly homologous muscle glycogen phosphorylase gene, PYGM, that underlie McArdle disease. There was heterogeneity in the clinical symptoms observed in affected individuals. These varied from hepatomegaly and subclinical hypoglycaemia, to severe hepatomegaly with recurrent severe hypoglycaemia and postprandial lactic acidosis. We conclude that deficiency of liver glycogen phosphorylase is predominantly the result of missense mutations affecting enzyme activity. There are no common mutations and the severity of clinical symptoms varies significantly.
糖原贮积病(GSD)VI型中肝糖原磷酸化酶的缺乏导致从糖原动员葡萄糖的能力降低。文献中已鉴定出编码该酶肝脏同工型的PYGL基因的六个突变。我们对来自七个家庭的八名GSD VI型患者进行了特征分析,并鉴定出11个新的PYGL基因缺陷。大多数突变是错义突变,导致高度保守残基的替代。这些突变可分为预计会影响底物结合的突变(p.V456M、p.E673K、p.S675L、p.S675T)、磷酸吡哆醛结合的突变(p.R491C、p.K681T)或糖原磷酸化酶激活的突变(p.Q13P),或者具有未知影响的突变(p.N632I和p.D634H)。预计两个突变会导致无效等位基因,即p.R399X和[c.1964_1969inv6;c.1969+1_+4delGTAC]。与导致McArdle病的高度同源的肌肉糖原磷酸化酶基因PYGM的68-80%的受影响等位基因相比,在已报道的23个(30%)PYGL等位基因中,只有7个携带无义、剪接位点或移码突变。在受影响个体中观察到临床症状存在异质性。这些症状从肝肿大和亚临床低血糖到严重肝肿大伴反复严重低血糖和餐后乳酸性酸中毒不等。我们得出结论,肝糖原磷酸化酶缺乏主要是影响酶活性的错义突变的结果。没有常见突变,临床症状的严重程度差异很大。